Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
AKTIENPREIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNwam Llc
Latest Disclosed Ownership914 shares
Latest Disclosed Value $ 302,415
Nwam Llc ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 4, 2026 - Nwam Llc filed a 13F-HR form disclosing ownership of 914 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $261,130 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 4, 2026 disclosing 914 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $230,145 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 914 0 0.00 302 -8.48 0.0174
2026-02-04 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 914 2 0.22 330 -26.17 0.0185
2026-02-04 2025-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 912 0 0.00 448 25.21 0.0243
2025-10-28 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 912 0 424 0.0298
2026-02-04 2025-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 912 5 0.55 358 46.31 0.0208
2025-08-07 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 912 5 310 0.0252
2025-05-05 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 907 1 0.11 245 14.55 0.0211
2025-02-05 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 906 50 5.84 213 -9.36 0.0132
2024-11-12 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 856 4 0.47 235 13.53 0.0144
2024-07-24 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 852 852 207 0.0608
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -850 -100.00 0 -100.00
2023-02-08 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 850 850 202 0.0179
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.